1
|
Diazonium-Modified Screen-Printed Electrodes for Immunosensing Growth Hormone in Blood Samples. BIOSENSORS-BASEL 2019; 9:bios9030088. [PMID: 31319551 PMCID: PMC6784379 DOI: 10.3390/bios9030088] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/01/2019] [Revised: 07/11/2019] [Accepted: 07/15/2019] [Indexed: 12/24/2022]
Abstract
Altered growth hormone (GH) levels represent a major global health challenge that would benefit from advances in screening methods that are rapid and low cost. Here, we present a miniaturized immunosensor using disposable screen-printed carbon electrodes (SPCEs) for the detection of GH with high sensitivity. The diazonium-based linker layer was electrochemically deposited onto SPCE surfaces, and subsequently activated using covalent agents to immobilize monoclonal anti-GH antibodies as the sensing layer. The surface modifications were monitored using contact angle measurements and X-ray photoelectron spectroscopy (XPS). The dissociation constant, Kd, of the anti-GH antibodies was also determined as 1.44 (±0.15) using surface plasmon resonance (SPR). The immunosensor was able to detect GH in the picomolar range using a 20 µL sample volume in connection with electrochemical impedance spectroscopy (EIS). The selectivity of the SPCE-based immunosensors was also challenged with whole blood and serum samples collected at various development stages of rats, demonstrating the potential applicability for detection in biological samples. Our results demonstrated that SPCEs provided the development of low-cost and single-use electrochemical immunosensors in comparison with glassy carbon electrode (GCE)-based ones.
Collapse
|
2
|
Maimaiti M, Tanahashi Y, Mohri Z, Fujieda K. Development of a bioassay system for human growth hormone determination with close correlation to immunoassay. J Clin Lab Anal 2013; 26:328-35. [PMID: 23001977 DOI: 10.1002/jcla.21527] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Serum growth hormone (GH) level is measured largely through immunoassays in clinical practice. However, a few cases with bioinactive and immunoreactive GH have also been reported. We describe here a new bioassay system for GH determination using the BaF/GM cell line, which proliferates in a dose-dependent manner on hGH addition; cell proliferation was blocked by anti-hGH antibody. This bioassay had the lowest detection limit (∼0.02 ng/ml) reported thus far and the highest specificity for GH. The bioassay results were compared with those of an immunoradiometric assay across 163 patient samples in various endocrine states. A close correlation (the ratio of bioactivity/immunoreactivity was 1.04 ± 0.33, mean ± SD) was observed between bioactivity and immunoreactivity in these samples. The newly developed system is a specific, sensitive, easy, and fast bioassay system for GH determination; we consider it useful for evaluating GH bioactivity in various endocrine states.
Collapse
Affiliation(s)
- M Maimaiti
- Department of Pediatrics, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
| | | | | | | |
Collapse
|
3
|
Bidlingmaier M, Freda PU. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm IGF Res 2010; 20:19-25. [PMID: 19818659 PMCID: PMC7748084 DOI: 10.1016/j.ghir.2009.09.005] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2009] [Accepted: 09/17/2009] [Indexed: 01/28/2023]
Abstract
Measuring the concentration of growth hormone (GH) in blood samples taken during dynamic tests represents the basis for diagnosis of growth hormone related disorders, namely growth hormone deficiency and growth hormone excess. Today, a wide spectrum of immunoassays are in use, enabling rapid and sensitive determination of growth hormone concentrations in routine diagnostics. From a clinical point of view several difficulties exist with the use and interpretation of GH assay results in the assessment of GH related disorders: Many physiological factors such as fat mass, age and gender influence the outcome of dynamic tests, overall leading to significant inter-individual differences in GH responses. However, in addition to the physiological variability, considerable variability exists in GH assay results obtained by different immunoassays. Unfortunately, all the new technical advances in the field of GH measurement techniques have not reduced this methodological variability. To a large extent, the actual values reported for the GH concentration in a sample depend on the method used by the respective laboratory. Obviously, such discrepancies limit the applicability of consensus guidelines on diagnosis and treatment in clinical practice. This review summarizes current practices for GH measurement with respect to the methods used, their limitations and the clinical consequences of the existing heterogeneity in GH immunoassay results.
Collapse
Affiliation(s)
- Martin Bidlingmaier
- Endocrine Research Laboratories, Medizinische Klinik - Innenstadt, Ludwig-Maximilians University, Munich, Germany.
| | | |
Collapse
|
4
|
Abstract
Measurement of circulating growth hormone (GH) concentrations is essential in diagnosis of either GH deficiency or GH excess. The invention of immunoassays for the measurement of peptide hormones was a major breakthrough, enabling the routine analysis of GH concentrations in larger series of samples. Over the last few decades, measurement technology has evolved from less sensitive, mainly radioactive assays based on polyclonal antisera to the latest generations of highly sensitive chemiluminescence methods employing monoclonal antibodies. Unfortunately, the development of newer assays did not lead to better agreement among the results obtained by different assay methods. On the contrary, the differences tended to increase when monoclonal antibody based assays became more popular. The actual value reported for the GH concentration in a specific patient's sample still mainly depends on the method used by the respective laboratory, limiting the applicability of international consensus guidelines in clinical practice. The heterogeneity of the analyte itself, the availability of different reference preparations for calibration and the interference from matrix components such as GH binding protein are among the reasons why standardizing GH assays is difficult. An additional challenge arose from the availability of a GH receptor antagonist for the treatment of acromegaly, which is basically a mutated form of GH and therefore interferes in many GH assays. This review provides an overview on GH assays used in clinical practice, their limitations and the potential next steps towards standardization.
Collapse
Affiliation(s)
- Martin Bidlingmaier
- Endocrine Research Laboratories, Medizinische Klinik-Innenstadt, Ludwig-Maximilians University, Ziemssenstr. 1, 80336 Munich, Germany.
| | | |
Collapse
|
5
|
Tanaka T, Tachibana K, Shimatsu A, Katsumata N, Tsushima T, Hizuka N, Fujieda K, Yokoya S, Irie M. A nationwide attempt to standardize growth hormone assays. HORMONE RESEARCH 2005; 64 Suppl 2:6-11. [PMID: 16286763 DOI: 10.1159/000087746] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The Growth Hormone (GH) and Its Related Factors Study Committee of the Foundation for Growth Science, Japan, has been conducting a quality control study for 15 years to improve the equality of diagnosis of GH deficiency. It found that the greatest differences in measured GH values were due to the different potencies of the kit standards, which were primarily adjusted to WHO standards for human GH of pituitary origin. With the collaboration of kit makers and the Study Group of Hypothalamo-Pituitary Disorders of the Ministry of Health, Labor and Welfare, all GH kits in Japan have begun using the same recombinant human GH standard since April 2005. As a result the diagnostic cut-off peak GH has changed from 10 to 6 ng/ml.
Collapse
Affiliation(s)
- Toshiaki Tanaka
- The GH and Its Related Factors Study Committee, The Foundation for Growth Science, Tokyo, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Popii V, Baumann G. Laboratory measurement of growth hormone. Clin Chim Acta 2004; 350:1-16. [PMID: 15530455 DOI: 10.1016/j.cccn.2004.06.007] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2004] [Revised: 06/04/2004] [Accepted: 06/07/2004] [Indexed: 11/24/2022]
Abstract
Growth hormone (GH) measurements are complicated by the heterogeneous nature of GH, as well as by the presence of the GH binding protein in plasma. Several isoforms of GH exist, and specific assays for each are currently either unavailable, impractical, or not clinically indicated. Bioassays include the in vivo assays based on rat weight gain, tibial line widening, or IGF-I generation. In vitro bioassays, based on the proliferation of cell lines expressing the prolactin receptor or GH receptor, are sensitive but prone to nonspecific interference by factors present in serum. Immunoassays (RIA, IRMA, ELISA, and immunofunctional assay design) are widely used in the clinical laboratory because of speed, sensitivity, and convenience. Discrepancies among results rendered by different immunoassays have become more apparent as monoclonal assays have superseded polyclonal assays, presumably because different antibodies recognize different epitopes among the heterogeneous mixture of GH isoforms in serum. Some assays, especially those with short, nonequilibrium incubation times are vulnerable to interference by the GH binding protein present in serum. Recommendations are given for strategies designed to minimize disparity of results obtained by different GH immunoassays applied to serum. Urinary GH measurements, while technically feasible, are of limited clinical utility because of biological variation in urinary GH excretion.
Collapse
Affiliation(s)
- Violeta Popii
- Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine and Veterans Administration Chicago Health Care System, 303 East Chicago Avenue, Chicago, Illinois 60611, USA
| | | |
Collapse
|
7
|
Moura JF, DeLacerda L, Sandrini R, Borba FM, Castelo DN, Sade ER, Sella S, Minozzo JC, Callefe LG, Figueiredo BC. ELISA for Determination of Human Growth Hormone: Recognition of Helix 4 Epitopes. J Biomed Biotechnol 2004; 2004:143-149. [PMID: 15292580 PMCID: PMC551587 DOI: 10.1155/s1110724304308090] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Human growth hormone (hGH) signal transduction initiates with a
receptor dimerization in which one molecule binds to the receptor
through sites 1 and 2. A sandwich enzyme-linked immunosorbent
assay was developed for quantifying hGH molecules that present
helix 4 from binding site 1. For this, horse anti-rhGH antibodies
were eluted by an immunoaffinity column constituted by
sepharose-rhGH. These antibodies were purified through a second
column with synthetic peptide correspondent to hGH helix
4, immobilized to sepharose, and used as capture antibodies.
Those that did not recognize synthetic peptide were used as a
marker antibody. The working range was of 1.95 to 31.25 ng/mL
of hGH. The intra-assay coefficient of variation (CV) was between
4.53% and 6.33%, while the interassay CV was between 6.00% and
8.27%. The recovery range was between 96.0% to 103.8%. There
was no cross-reactivity with human prolactin. These features show
that our assay is an efficient method for the determination of hGH.
Collapse
Affiliation(s)
- Juliana F. Moura
- Center for Molecular Genetics and Childhood Cancer Research
(CEGEMPAC), Rua Agostinho Leão Júnior, 400 Alto da Glòria, Curitiba, PR, Brazil
| | - Luiz DeLacerda
- Division of Pediatrics Endocrinology, Department of Pediatrics,
Federal University of Paraná, Curitiba, PR, Brazil
| | - Romolo Sandrini
- Division of Pediatrics Endocrinology, Department of Pediatrics,
Federal University of Paraná, Curitiba, PR, Brazil
| | - Fernanda M. Borba
- Division of Pediatrics Endocrinology, Department of Pediatrics,
Federal University of Paraná, Curitiba, PR, Brazil
| | - Denise N. Castelo
- Division of Pediatrics Endocrinology, Department of Pediatrics,
Federal University of Paraná, Curitiba, PR, Brazil
| | - Elis R. Sade
- Center for Molecular Genetics and Childhood Cancer Research
(CEGEMPAC), Rua Agostinho Leão Júnior, 400 Alto da Glòria, Curitiba, PR, Brazil
| | - Sandra Sella
- Center for Research and Production of Immunoglobulins (CPPI), Piraquara, PR, Brazil
| | - João C. Minozzo
- Center for Research and Production of Immunoglobulins (CPPI), Piraquara, PR, Brazil
| | - Luis G. Callefe
- Center for Molecular Genetics and Childhood Cancer Research
(CEGEMPAC), Rua Agostinho Leão Júnior, 400 Alto da Glòria, Curitiba, PR, Brazil
| | - Bonald C. Figueiredo
- Center for Molecular Genetics and Childhood Cancer Research
(CEGEMPAC), Rua Agostinho Leão Júnior, 400 Alto da Glòria, Curitiba, PR, Brazil
- *Bonald C. Figueiredo:
| |
Collapse
|
8
|
Boguszewski CL. Molecular heterogeneity of human GH: from basic research to clinical implications. J Endocrinol Invest 2003; 26:274-88. [PMID: 12809181 DOI: 10.1007/bf03345170] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- C L Boguszewski
- Service of Endocrinology and Metabolism, Clinical Hospital, Federal University of Paraná (SEMPR), Department of Internal Medicine, Curitiba, Brazil.
| |
Collapse
|
9
|
Rowland JE, Marshall NJ, Leung KC, Ho KKY, Cotterill AM, Rowlinson SW, Waters MJ. A novel bioassay for human somatogenic activity in serum samples supports the clinical reliability of immunoassays. Clin Endocrinol (Oxf) 2002; 56:475-85. [PMID: 11966740 DOI: 10.1046/j.1365-2265.2002.01507.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE Because there is discordance between different immunoassay values for serum hGH, and because clinical state may not correlate with immunoreactive hGH, we have developed an assay to accurately measure serum hGH somatogenic bioactivity. The results of this assay were compared with the Elegance two-site ELISA assay across 135 patient samples in a variety of clinical states. DESIGN The somatogenic assay was based on stable expression of hGH receptor in the murine BaF line, allowing these cells to proliferate in response to hGH. To eliminate interference by other growth factors in serum, we created a specific antagonist of the hGH receptor (similar to Trovert or Pegvisomant) which allowed us to obtain a true measure of hGH somatogenic activity by subtraction of the activity in the presence of the antagonist. The assay was carried out in microtiter plates over 24 h, with oxidation of a chromogenic tetrazolium salt (MTT) as the endpoint. PATIENTS These encompassed a number of different clinical conditions related to short stature, including idiopathic short stature, neurosecretory dysfunction and renal failure, as well as obese patients on dietary restriction and normal volunteers. MEASUREMENTS In addition to the colourimetric (MTT) response to hGH, we measured free hGH by stripping out GHBP-bound hGH using beads coupled to a monoclonal antibody to the GHBP (GH binding protein). All samples were measured in both bioassay and ELISA assay. RESULTS This bioassay was sensitive (5 mU/l or 2 microg/l) and precise, and not subject to interference by the GHBP. There was a good correlation (r = 0.95) between bioactivity and immunoactivity across clinical states. There was, however, an increased bioactivity during secretory peaks (over 25 mU/l), which has been reported previously for the Nb2 bioassay. Free hGH did not correlate with clinical state. CONCLUSIONS Because the results of the Elegance ELISA and the bioassay correlate well, even though there is greater bioactivity at higher hormone concentrations, it is evident that an appropriate immunoassay is able to act as a reliable indicator for clinical assessment. In those rare cases where bio-inactive GH exists, our bioassay should provide an appropriate means to demonstrate this.
Collapse
Affiliation(s)
- Jennifer E Rowland
- Department of Physiology & Pharmacology and Centre for Molecular & Cellular Biology, University of Queensland, St Lucia, Australia 4072
| | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Serum human growth hormone (hGH) assays show a wide range in bias and in cut-off values for provocative tests, which vary from 13.5 to 35-40 mU/L when they have been established. Studies using novel hGH assays show that methods that are absolutely specific for 22-kDa hGH may not identify bioactive hGH peaks and that 20:22-kDa hGH ratios are increased in acromegaly. Greater harmonization of serum hGH methods can be achieved by: changing from IS 80/505 to IS 98/574, which is calibrated in mass units of recombinant 22-kDa hGH; using monoclonal/polyclonal or polyclonal/polyclonal antibody combinations that measure both 20-kDa and 22-kDa hGH; the development of assays such as the immunofunctional hGH assay which has the convenience of an immunometric assay but gives results that correlate better with bioassays collaboration between manufacturers and laboratories to establish method-related cut-off limits for provocative tests of hGH status.
Collapse
Affiliation(s)
- P Wood
- Department of Chemical Pathology, Southampton General Hospital, UK.
| |
Collapse
|
11
|
Rakover Y, Lavi I, Masalah R, Issam T, Weiner E, Ben-Shlomo I. Comparison between four immunoassays for growth hormone (GH) measurement as guides to clinical decisions following GH provocative tests. J Pediatr Endocrinol Metab 2000; 13:637-43. [PMID: 10905388 DOI: 10.1515/jpem.2000.13.6.637] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVE To compare four assays for the measurement of GH following provocative tests and to assess the projected clinical decisions, which would have been based on their respective results. DESIGN Multiple assays of serum samples obtained during provocative tests for GH response. SUBJECTS Forty-seven children with short stature, who underwent clinical evaluation and GH provocative tests. METHODS All samples were measured by the immunoassay Sorin-RIA (A), which is routinely used in our laboratory. Basal and peak samples were analyzed by three other immunoassays: Sorin-IRMA (B), DPC-RIA (C) and Wallac-DELFIA (D). Results were classified as low, partial and normal GH response, corresponding to <10, 10-17.9 and >18 microIU/ml peak serum GH levels. RESULTS High correlation was found between individual results by the four kits (r=0.92-0.94). However, the mean peak GH values were significantly different (p<0.0001). Further analysis using paired t-test has shown highly significant differences between the assays (p<0.0001) apart from assays A and B that were not significantly different. Clinical grouping by the four tests was profoundly different: by assay A, 14.9% were judged low response and 57.4% normal; by assay D, 36.2% were low and only 21.3% normal. Kappa statistics measurement demonstrated poor agreement between assays A and D and between B and D. CONCLUSION As the criteria for the diagnosis of GH deficiency and the indications for GH therapy are based on laboratory GH results, more must be done to ensure uniformity and comparability of the GH assays.
Collapse
Affiliation(s)
- Y Rakover
- Pediatric Endocrine Unit, Ha'Emek Medical Center, Afula, Israel.
| | | | | | | | | | | |
Collapse
|
12
|
Bozzola M, Radetti G, Elmlinger M, Strasburger CJ. [Does the growth hormone pharmacokinetic profile help to predict the treatment response?]. Arch Pediatr 2000; 5 Suppl 4:322S-326S. [PMID: 9853077 DOI: 10.1016/s0929-693x(99)80184-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Pharmacokinetics of subcutaneously administered recombinant growth hormone (rGH) were studied in nine GH deficient children at the time of the first rGH injection at the beginning of treatment. Serum GH levels were determined by four different methods: immunofunctional assay, immunofluorometric assay and two bioassays on Nb2 cells. The results showed similar profiles whatever the type of assay with a concentration peak reached 2 to 6 hours after subcutaneous injection; however, large individual variations in peak amplitude were observed. They were related to individual variations in the growth velocity during the first year of rGH treatment. These variations are possibly related to individual differences in rGH degradation at the site of injection. Study of rGH absorption profiles appears useful in the evaluation of rGH treatment in GH deficient patients.
Collapse
Affiliation(s)
- M Bozzola
- Département de pédiatrie, policlinico San Matteo, Pavia, Italie
| | | | | | | |
Collapse
|
13
|
Bozzola M, Radetti G, Buzi F, Tonini G, Moretta A, Autelli M, Aglialoro A, Rondini G, Barreca A. Growth hormone bioactivity and immunoactivity in tall children. J Endocrinol Invest 1999; 22:541-6. [PMID: 10475152 DOI: 10.1007/bf03343606] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In subjects with constitutional tall stature, both low and high GH response to stimulation tests have been observed when measured by commercial kits. To investigate the reason for these conflicting results, we evaluated growth hormone (GH) secretion using different assays as well as GH-binding protein and insulin-like growth factor-I (IGF-I) concentrations in tall children. Serum samples were collected from 22 prepubertal constitutionally tall children, aged 2.87-13.25 years, during two pharmacological tests to evaluate serum GH levels measured by both immunofluorometric assay (IFMA) and the Nb2 cell bioassay. Serum IGF-I values were evaluated by RIA. Circulating low affinity (LA) and high affinity (HA) GH-binding proteins (GHBPs) were evaluated by FPLC gel filtration. Considering the highest serum GH levels as measured by IFMA, the 22 tall subjects were divided into two groups: group A including 16 children with blunted serum GH peak levels (5.78+/-0.68 ng/ml) and group B including 6 subjects with normal serum GH peak values (15.73+/-1.56 ng/ml). No differences were observed in serum GH peak levels as measured by the Nb2 cell bioassay between group A (14.77+/-1.54 ng/ml) and group B (16.03+/-1.96 ng/ml), and between both groups and 11 age-and sex-matched controls (12.25+/-1.19 ng/ml). In group A, the Nb2 cell bioassay/IFMA ratio of serum GH peak levels (0.29+/-0.08) was significantly higher (p<0.05) than in group B (0.07+/-0.01). No differences were found in serum LA-GHBP and HA-GHBP as well as in IGF-I concentrations between the 16 patients of group A and the 6 of group B. Likewise, no difference in auxological parameters was found between the two groups. The biological activity of GH evaluated using the Nb2 cell bioassay is similar in tall children with a low GH response as measured by IFMA in comparison with those with a normal GH response, and is in agreement with both the auxological data and serum IGF-I concentrations.
Collapse
Affiliation(s)
- M Bozzola
- Dipartimento di Scienze Pediatriche, Università di Pavia, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Binder G, Benz MR, Elmlinger M, Pflaum CD, Strasburger CJ, Ranke MB. Reduced human growth hormone (hGH) bioactivity without a defect of the GH-1 gene in three patients with rhGH responsive growth failure. Clin Endocrinol (Oxf) 1999; 51:89-95. [PMID: 10468970 DOI: 10.1046/j.1365-2265.1999.00744.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND A GH deficiency-like phenotype with normal or high hGH secretion, pathologically low IGF-I serum levels, and catch-up growth under treatment with recombinant hGH is suggestive of the presence of biologically inactive hGH syndrome, whose presumably heterogenous molecular basis is substantially unknown. DESIGN Serum samples from patients who fulfilled the above criteria and from controls with idiopathic short stature were measured by polyclonal hGH-RIA, Nb2 rat lymphoma proliferation assay, and hGH immunofunctional assay (IFA). If assays were suggestive of the presence of bioinactive GH, mutational analysis of the hGH-1 gene was performed. PATIENTS Three patients were selected because of clinical and biochemical evidence. At the time of diagnosis mean age was 3.4 (2.2, 3.5, 4.5) years, mean height -3.5 (-2.8, -3.6, -4.2) SD score (SDS) and mean growth rate -1.5 (-1.4, -1.5, -1.6) SDS. Mean IGF-I serum levels were -1.9 (-0.7, -2.4, -2.5) SDS and mean IGFBP-3 serum levels -1.2 (-1.1, -1.2, -1.2) SDS. Stimulated and spontaneous GH peaks measured by a polyclonal radioimmunoassay were all above 14 microg/l. GHBP serum levels were normal, and antihGH antibodies were not detected. Therapy with rhGH was effective in causing catch-up growth of the three children with an initial mean growth rate of + 2.9 (+ 1.7, + 2.1, + 5.0) SDS, and normalization of IGF-I (mean: -0.66 SDS: -1.8, - 1.2, + 1.1 SDS) and IGFBP-3 serum levels (mean: + 0.81 SDS: -0.2, + 0.8, + 1.8 SDS). RESULTS In comparison to controls, the patients' serum hGH levels were much lower when measured by Nb2 rat lymphoma cell proliferation bioassay (mean: -2.3 SDS, range: -1.7- -4.1) and by the immunofunctional assay (IFA) (-1.5 SDS, range: -0.2- -3.1) than by RIA. Retesting of two of the three patients including an one year break of therapy confirmed the rhGH dependence of growth in spite of normal endogenous GH secretion. Radioactive direct sequencing of both strands of PCR-amplified genomic DNA and cDNA excluded a GH-1 gene mutation in all three children. CONCLUSION Mutations of the GH-1 gene are probably not the main genetic defect in children with biologically inactive hGH syndrome. Posttranslational processing of hGH might reduce the biological activity of the normal translation product.
Collapse
Affiliation(s)
- G Binder
- University-Children's Hospital and Growth Research Centre, Tübingen, Germany
| | | | | | | | | | | |
Collapse
|
15
|
Bozzola M, Zecca M, Locatelli F, Radetti G, Pagani S, Autelli M, Tatò L, Chatelain P. Evaluation of growth hormone bioactivity using the Nb2 cell bioassay in children with growth disorders. J Endocrinol Invest 1998; 21:765-70. [PMID: 9972677 DOI: 10.1007/bf03348043] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The Nb2 cell bioassay could be a useful tool for evaluating human growth hormone (hGH) bioactivity, but is not specific for hGH since it relies on the ability of the hormone to produce effects by cross-reacting with the lactogenic receptor on Nb2 cells. We studied the biological activity of both endogenous and exogenous hGH in short patients using the Nb2 bioassay after inhibiting the mitogenic effect of the other lactogenic hormone, that is human prolactin (hPRL), by adding a specific antibody against hPRL to each assay. The in vitro study showed a significant (p<0.0001) increase in Nb2 cell proliferation when increasing concentrations of highly purified hGH were added to the cell culture. A complete inhibition of Nb2 cell replication was observed after adding a specific antibody against hGH. The in vivo study showed a significantly (p<0.0001) lower hGH bioactivity (4.90+/-0.28 ng/ml) evaluated during stimulation tests in 9 children with total idiopathic GH deficiency, mean age 9.25+/-1.99 years, in comparison with that found in 11 short children with normal growth velocity, mean age 8.22+/-1.41 years (12.25+/-1.19 ng/ml). Likewise, serum GH levels measured by immunofluorometric assay IFMA in the same serum samples were significantly (p<0.001) lower in the 9 GH-deficient (1.97+/-0.37 ng/ml) than in the 11 short children (21.85+/-2.71 ng/ml). Moreover, we evaluated GH concentrations using both IFMA and the Nb2 cell bioassay in serum samples collected from another 11 idiopathic GH-deficient children, mean age 10.71+/-1.18 years, before and then, 6 and 24 hours following the 1 st injection of r-hGH (0.1 IU/kg sc). Serum GH values measured by both IFMA and Nb2 bioassay significantly (p<0.0001) increased 6 hours after r-hGH administration and decreased to reach basal levels after 24 hours. In conclusion, the Nb2 cell bioassay with minor modifications seems to provide a specific and sensitive assessment of hGH bioactivity.
Collapse
Affiliation(s)
- M Bozzola
- Department of Paediatrics, University of Pavia, IRCCS Policlinico San Matteo, Italy
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Strasburger CJ, Dattani MT. New growth hormone assays: potential benefits. ACTA PAEDIATRICA (OSLO, NORWAY : 1992). SUPPLEMENT 1997; 423:5-11. [PMID: 9401531 DOI: 10.1111/j.1651-2227.1997.tb18361.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Three recently published new assays are described for the measurement of growth hormone (GH). Two of these--the eluted stain assay (ESTA) and the immunofunctional assay (IFA)--have been developed to measure the bioactivity of GH, rather than the immunoactivity as measured by conventional radioimmunoassays (RIAs). The third assay--the 22 kDa exclusion assay (22 k GHEA)--is designed to measure the concentrations of the different isoforms of GH present in the circulation. The ESTA is a variant of the Nb2 bioassay for lactogenic hormones, but has been adapted for specific GH measurement in serum samples. It has a lower detection limit than previous bioassays and permits the quantification of GH in large series of samples. The IFA uses a binding-site-specific antibody in combination with GH-binding protein (GHBP) in order to quantify only those GH molecules that are able to dimerize the extracellular domain of the GH receptor (GHBP), which is a prerequisite for GH signal transduction in target cells. The IFA is as convenient to use as immunoassays and can be employed routinely for GH determinations. The clinical usefulness of the 22 k GHEA has not been established, but it should provide a means of augmenting our understanding of the regulation of GH and its various isoforms. Once the ESTA bioassay or the IFA become commercially and widely available, either could replace the RIA as the standard reference method for measuring GH, as both more closely reflect the biologically active proportion of GH in serum samples than that measured by RIA.
Collapse
Affiliation(s)
- C J Strasburger
- Department of Medicine, Innenstadt University Hospital, Ludwig-Maximilians-University, Munich, Germany
| | | |
Collapse
|
17
|
Baumann G, Shaw M, Amburn K, Jan T, Davila N, Mercado M, Stolar M, MacCart J. Heterogeneity of circulating growth hormone. Nucl Med Biol 1994; 21:369-79. [PMID: 9234302 DOI: 10.1016/0969-8051(94)90060-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Human growth hormone (GH) represents a family of related proteins arising from two genes, alternative mRNA splicing, and several post-translational modifications. In addition, post-secretory events occur when GH enters the circulation. The full scale of GH heterogeneity is only beginning to be appreciated, and new GH forms or related proteins may be discovered in the future. GH measurements are affected by GH heterogeneity. Immunoassays are influenced by the mixture of GH variants, but are not sensitive to GH binding proteins (GHBPs). In contrast, radioreceptor assays are sensitive to both GH variant mixtures and to the high affinity GHBP. It is hoped that in the future, these problems can be minimized by rigorous characterization of existing antibodies with respect to epitope recognition on various GH forms, and ultimately, by production of GH variant-specific antibodies that permit direct and individual assessment of the circulating members of the GH family.
Collapse
Affiliation(s)
- G Baumann
- Departement of Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
Urinary growth hormone reflects plasma levels, if a normal renal function is assured. It offers the advantages of easy repetition over prolonged periods of time. It is an easy tool to assess physiological and pathophysiological aspects of the "amount" of growth hormone secreted in a given clinical situation. It can be used to control therapy and reassess the "growth hormone status" at any time during a treatment period. It cannot, however, replace the assessment of responses of the system to a given stimulus and will not reflect the pulsatility of plasma levels.
Collapse
Affiliation(s)
- J Girard
- Endocrine clinic and laboratory, Basel, Switzerland
| |
Collapse
|
19
|
|